NCT04559971View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

March 23, 2021

Study Completion Date

March 23, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

SLN124

SLN124 for subcutaneous (s.c.) injection

DRUG

Placebo

Sodium chloride for s.c. injection

Trial Locations (1)

Unknown

Hammersmith Medicines Research, London

All Listed Sponsors
lead

Silence Therapeutics plc

INDUSTRY

NCT04559971 - A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers | Biotech Hunter | Biotech Hunter